Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
PaperCitations, authors & open-access status
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1,117 citations, 2008 year and hybrid oa status.
1,117
Citations
2008
Year
hybrid
OA Status